Stein Schalkwijk1, Rick Greupink2, Angela P Colbers3, Alfons C Wouterse2, Vivienne G M Verweij2, Joris van Drongelen4, Marga Teulen3, Daphne van den Oetelaar2, David M Burger3, Frans G M Russel5. 1. Department of Pharmacy, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen 6500 HB, The Netherlands Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen 6500 HB, The Netherlands. 2. Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen 6500 HB, The Netherlands. 3. Department of Pharmacy, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen 6500 HB, The Netherlands. 4. Department of Obstetrics and Gynecology, Radboud university medical center, Nijmegen 6500 HB, The Netherlands. 5. Department of Pharmacology and Toxicology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen 6500 HB, The Netherlands frans.russel@radboudumc.nl.
Abstract
OBJECTIVES: Data on fetal exposure to antiretroviral agents during pregnancy are important to estimate their potential for prevention of mother-to-child transmission (PMTCT) and possible toxicity. For the recently developed HIV integrase inhibitor dolutegravir, clinical data on fetal disposition are not yet available. Dual perfusion of a single placental lobule (cotyledon) provides a useful ex vivo model to predict the in vivo maternal-to-fetal transfer of this drug. The aim of this study was to estimate the transfer of dolutegravir across the human term placenta, using a dual-perfusion cotyledon model. METHODS: After cannulation of the cotyledons (n = 6), a fetal circulation of 6 mL/min and maternal circulation of 12 mL/min were initiated. The perfusion medium consisted of Krebs-Henseleit buffer (pH = 7.2-7.4) supplemented with 10.1 mM glucose, 30 g/L human serum albumin and 0.5 mL/L heparin 5000IE. Dolutegravir was administered to the maternal circulation (∼ 4.2 mg/L) and analysed by UPLC-MS/MS. RESULTS: After 3 h of perfusion, the mean ± SD fetal-to-maternal (FTM) concentration ratio of dolutegravir was 0.6 ± 0.2 and the mean ± SD concentrations in the maternal and fetal compartments were 2.3 ± 0.4 and 1.3 ± 0.3 mg/L, respectively. CONCLUSIONS: Dolutegravir crosses the blood-placental barrier with a mean FTM concentration ratio of 0.6. Compared with other antiretroviral agents, placental transfer of dolutegravir is moderate to high. These data suggest that dolutegravir holds clinical potential for pre-exposure prophylaxis and consequently PMTCT, but also risk of fetal toxicity.
OBJECTIVES: Data on fetal exposure to antiretroviral agents during pregnancy are important to estimate their potential for prevention of mother-to-child transmission (PMTCT) and possible toxicity. For the recently developed HIV integrase inhibitor dolutegravir, clinical data on fetal disposition are not yet available. Dual perfusion of a single placental lobule (cotyledon) provides a useful ex vivo model to predict the in vivo maternal-to-fetal transfer of this drug. The aim of this study was to estimate the transfer of dolutegravir across the human term placenta, using a dual-perfusion cotyledon model. METHODS: After cannulation of the cotyledons (n = 6), a fetal circulation of 6 mL/min and maternal circulation of 12 mL/min were initiated. The perfusion medium consisted of Krebs-Henseleit buffer (pH = 7.2-7.4) supplemented with 10.1 mM glucose, 30 g/L human serum albumin and 0.5 mL/L heparin 5000IE. Dolutegravir was administered to the maternal circulation (∼ 4.2 mg/L) and analysed by UPLC-MS/MS. RESULTS: After 3 h of perfusion, the mean ± SD fetal-to-maternal (FTM) concentration ratio of dolutegravir was 0.6 ± 0.2 and the mean ± SD concentrations in the maternal and fetal compartments were 2.3 ± 0.4 and 1.3 ± 0.3 mg/L, respectively. CONCLUSIONS:Dolutegravir crosses the blood-placental barrier with a mean FTM concentration ratio of 0.6. Compared with other antiretroviral agents, placental transfer of dolutegravir is moderate to high. These data suggest that dolutegravir holds clinical potential for pre-exposure prophylaxis and consequently PMTCT, but also risk of fetal toxicity.
Authors: Bassam H Rimawi; Erica Johnson; Augustine Rajakumar; Sijia Tao; Yong Jiang; Scott Gillespie; Raymond F Schinazi; Mark Mirochnick; Martina L Badell; Rana Chakraborty Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191
Authors: Xiaomei I Liu; Jeremiah D Momper; Natella Y Rakhmanina; Dionna J Green; Gilbert J Burckart; Tim R Cressey; Mark Mirochnick; Brookie M Best; John N van den Anker; André Dallmann Journal: Clin Pharmacokinet Date: 2020-11 Impact factor: 6.447
Authors: Stein Schalkwijk; Aaron O Buaben; Jolien J M Freriksen; Angela P Colbers; David M Burger; Rick Greupink; Frans G M Russel Journal: Clin Pharmacokinet Date: 2018-06 Impact factor: 6.447
Authors: Dorien Feyaerts; Joshua Gillard; Bram van Cranenbroek; Lina Rigodanzo Marins; Mariam M S Baghdady; Gaia Comitini; A Titia Lely; Henk W van Hamersvelt; Olivier W H van der Heijden; Irma Joosten; Renate G van der Molen Journal: Front Immunol Date: 2021-10-28 Impact factor: 7.561
Authors: Kimberly K Scarsi; Joshua P Havens; Anthony T Podany; Sean N Avedissian; Courtney V Fletcher Journal: Drugs Date: 2020-11 Impact factor: 9.546